Merus (MRUS) details Genmab $97 cash offer and cancelled stock options
Rhea-AI Filing Summary
Merus N.V. reports how its Chief Medical Officer’s equity was treated in connection with a change-of-control transaction involving Genmab. Genmab’s wholly owned subsidiary commenced a tender offer for all issued and outstanding Merus common shares, and on December 12, 2025 accepted all shares that were validly tendered in exchange for a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
On the same date, stock options with exercise prices of $41.65 and $54.45, covering 50,000 and 183,943 Merus common shares respectively, were cancelled under the transaction agreement. In place of these options, the reporting person became entitled to cash equal to the amount by which the $97.00 offer price exceeded each option’s exercise price, multiplied by the number of underlying shares, leaving zero derivative securities from these grants outstanding.
Positive
- Genmab tender offer accepted at $97.00 per Merus share, providing a cash exit for tendering shareholders and cash settlement for related stock options.
Negative
- None.
Insights
Genmab’s cash tender offer for Merus converts insider stock options into cash based on the spread over their exercise prices.
The disclosure describes a change-of-control event where a Genmab subsidiary launched a tender offer for all issued and outstanding Merus N.V. common shares at $97.00 per share in cash. As of the acceptance time on December 12, 2025, all shares validly tendered into the offer were accepted for this fixed cash consideration, creating a clear liquidity outcome for participating shareholders.
For the Chief Medical Officer, equity incentives in the form of stock options were settled in cash rather than remaining as derivative exposure. Options with exercise prices of $41.65 and $54.45, covering 50,000 and 183,943 common shares, were cancelled under the transaction agreement. The holder instead receives cash equal to the excess of the $97.00 offer price over each option’s exercise price, multiplied by the relevant share count.
After this treatment, the table shows zero derivative securities remaining from these grants, indicating that the options have been fully cashed out. This aligns insider incentives with the cash consideration received by common shareholders and removes future dilution from these particular option awards, consistent with typical treatment in an all-cash tender offer structure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Share Option (right to buy) | 50,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 183,943 | $0.00 | -- |
Footnotes (1)
- On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
FAQ
How were the Merus (MRUS) Chief Medical Officer’s stock options treated?
The Chief Medical Officer’s stock options were cancelled under the transaction agreement. In exchange, the holder became entitled to cash equal to the amount by which the $97.00 offer consideration exceeded the applicable exercise price per share of each option, multiplied by the aggregate number of Merus shares underlying that option.
What option grants and exercise prices are disclosed for the Merus (MRUS) officer?
The filing shows two stock option grants described as "Share Option (right to buy)" with exercise prices of $41.65 and $54.45 per share. These options related to 50,000 and 183,943 underlying Merus common shares, respectively, and had stated expiration dates of January 29, 2035 and June 30, 2034 before being cancelled.
Does the reporting person still hold these Merus (MRUS) options after the transaction?
No. After the tender offer–related cash settlement, the table reports that the number of derivative securities beneficially owned from these specific option grants is 0, indicating that they were fully cancelled and converted into a right to receive cash.
What is the role of the reporting person at Merus (MRUS)?
The reporting person is identified as an officer of Merus N.V., holding the title of Chief Medical Officer, rather than a director or 10% owner.
When is the key transaction date for the Merus (MRUS) tender offer and option cancellation?
The key date is December 12, 2025, which is reported both as the transaction date for the derivative securities and as the acceptance time when the purchaser accepted all Merus shares that were validly tendered into the $97.00-per-share cash offer.